8-K: PetVivo Holdings Appoints Garry Lowenthal as Chief Financial Officer

PetVivo Holdings, Inc. has appointed Garry Lowenthal as its new Chief Financial Officer, effective March 8, 2024.

Summary

• PetVivo Holdings, Inc. has appointed Garry Lowenthal as its Chief Financial Officer, effective March 8, 2024.
• Mr. Lowenthal brings over 25 years of experience in senior operations and finance management.
• He has a background in equity capital raising, including private placements and public offerings.
• His previous roles include Managing Partner at Security First International, Inc., and CFO positions at Elate Group, Inc. and Fision Corporation.
• Mr. Lowenthal will receive an annual base salary of $200,000, paid to his holding company, Security First International, Inc.
• He will also receive a signing bonus of $10,000 and is eligible for performance-based bonuses.
• He will be granted 90,000 restricted stock units (RSUs), vesting in two tranches on January 28, 2025 and January 28, 2026.
• The employment agreement is for a term of approximately three years, terminating on March 31, 2027.

Sentiment

Score: 8

Explanation: The appointment of an experienced CFO is a positive development for the company, suggesting a focus on financial stability and growth. The terms of the agreement are standard and do not raise any concerns.

Positives

• The appointment of Garry Lowenthal brings significant financial expertise to PetVivo.
• Mr. Lowenthal's extensive experience in both private and public companies is a valuable asset.
• His background in equity capital raising could be beneficial for future funding needs.
• The employment agreement includes performance-based bonuses, aligning his interests with the company's success.
• The vesting schedule of the RSUs provides an incentive for long-term commitment.

Risks

• The company is subject to a non-competition covenant for one year after termination of employment.
• The company is subject to a non-solicitation covenant with respect to the company's employees for one year following termination of his employment.
• The company is subject to a customary confidentiality covenant.

Future Outlook

The company expects Mr. Lowenthal to help execute on the company's priorities, accelerate growth, and enhance value for all shareholders.

Management Comments

• John Lai, Chief Executive Officer of PetVivo Holdings, Inc., stated that they are incredibly excited to have Garry join the PetVivo management team.
• Mr. Lowenthal stated that he is thrilled to join PetVivo, a company whose technology could truly enhance the lives of companion animals.
• Mr. Lowenthal also stated that PetVivo has unique strengths, a strong business model, experienced management and personnel and an innovative technology.

Industry Context

This appointment is part of PetVivo's strategy to strengthen its management team as it focuses on commercializing innovative medical devices and therapeutics for companion animals.

Comparison to Industry Standards

• The compensation package for the CFO, including a $200,000 base salary and equity grants, is within the typical range for a company of PetVivo's size and stage in the biomedical device industry.
• The vesting schedule of the restricted stock units is a common practice to incentivize long-term performance and retention.
• The non-compete and non-solicitation clauses are standard in executive employment agreements to protect the company's interests.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of an experienced CFO as a positive step towards financial stability and growth.
• Employees may benefit from the leadership and expertise of the new CFO.
• Customers and suppliers may not be directly impacted by this appointment.

Next Steps

• Mr. Lowenthal will assume his responsibilities as CFO.
• The company will continue to execute its business plan.
• The company will consider performance-based bonuses for Mr. Lowenthal on a regular basis, at least once each calendar year.

Key Dates

Keywords

Chief Financial Officer, CFO, Garry Lowenthal, PetVivo Holdings, executive appointment, restricted stock units, equity compensation, financial management, corporate governance, biomedical devices